Literature DB >> 23597928

In vivo depletion of leukocytes and platelets following injection of T cell-specific antibodies into mice.

Lionel Loubaki1, Tony Tremblay, Renée Bazin.   

Abstract

In vivo T cell depletion experiments are widely used to establish the role of these cells in a variety of immunological processes. Different clones of monoclonal antibody targeting the CD3 molecular complex (mainly 145-2C11 and 17A2) have been successfully used for T cell depletion. In the present work, we assessed the specificity of monoclonal antibody-mediated CD3 T cell depletion in mouse peripheral blood. We showed that treatment of BALB/C mice with monoclonal antibodies (clones 145-2C11 and 17A2) not only efficiently depletes T cells in vivo, but also leads to a substantial reduction in B cell, granulocyte and platelet counts. In contrast, T cell depletion using a combination of anti-CD4 and anti-CD8 antibodies was efficient and produced less deleterious effects on other blood cell populations. Therefore, the results obtained from T cell depletion experiments using anti-CD3 antibodies must be interpreted with caution prior to draw definitive conclusions on the role of T cells in a given immunological process.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597928     DOI: 10.1016/j.jim.2013.04.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling.

Authors:  Wei Ying; Joshua Wollam; Jachelle M Ofrecio; Gautam Bandyopadhyay; Dalila El Ouarrat; Yun Sok Lee; Da Young Oh; Pingping Li; Olivia Osborn; Jerrold M Olefsky
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

2.  CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.

Authors:  Christopher M Coleman; Jeanne M Sisk; Gabor Halasz; Jixin Zhong; Sarah E Beck; Krystal L Matthews; Thiagarajan Venkataraman; Sanjay Rajagopalan; Christos A Kyratsous; Matthew B Frieman
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift.

Authors:  Azadeh Kheirolomoom; Aris J Kare; Elizabeth S Ingham; Ramasamy Paulmurugan; Elise R Robinson; Mo Baikoghli; Mohammed Inayathullah; Jai W Seo; James Wang; Brett Z Fite; Bo Wu; Spencer K Tumbale; Marina N Raie; R Holland Cheng; Lisa Nichols; Alexander D Borowsky; Katherine W Ferrara
Journal:  Biomaterials       Date:  2021-12-29       Impact factor: 12.479

4.  Possible role of arginase-1 in concomitant tumor immunity.

Authors:  Michael J Korrer; Yuwen Zhang; John M Routes
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

5.  Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.

Authors:  Denis R Beckford Vera; Christof C Smith; Lisa M Bixby; Dylan M Glatt; Stuart S Dunn; Ryoichi Saito; William Y Kim; Jonathan S Serody; Benjamin G Vincent; Matthew C Parrott
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

6.  YAP/TAZ direct commitment and maturation of lymph node fibroblastic reticular cells.

Authors:  Sung Yong Choi; Hosung Bae; Sun-Hye Jeong; Intae Park; Hyunsoo Cho; Seon Pyo Hong; Da-Hye Lee; Choong-Kun Lee; Jin-Sung Park; Sang Heon Suh; Jeongwoon Choi; Myung Jin Yang; Jeon Yeob Jang; Lucas Onder; Jeong Hwan Moon; Han-Sin Jeong; Ralf H Adams; Jin-Man Kim; Burkhard Ludewig; Joo-Hye Song; Dae-Sik Lim; Gou Young Koh
Journal:  Nat Commun       Date:  2020-01-24       Impact factor: 14.919

Review 7.  Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.

Authors:  Dario Gosmann; Lisa Russelli; Angela M Krackhardt; Calogero D'Alessandria; Wolfgang A Weber; Markus Schwaiger
Journal:  EJNMMI Res       Date:  2022-01-31       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.